This theme brings together companies whose core business is developing medicines, vaccines and tests for serious illness. It includes large pharmaceutical companies with broad portfolios, biotechnology companies focused on cancer, obesity and metabolic disease, and rare and immune disorders, plus diagnostics companies that help detect disease earlier. Healthcare and biotech ETFs add broader exposure. Drug development is long and uncertain, and trial results, regulatory decisions and pricing policy can move these stocks sharply.
Note: This Public Theme is based on data from one or more third-party data providers. This Theme is provided for informational purposes only by Public Holdings, Inc., and is not investment advice or an investment recommendation. You should not buy or sell anything included in this Public Theme without first determining it is appropriate for your portfolio or investment strategy. Investors should consider the investment objectives and unique risk profile of an Exchange Traded Product (“ETP”) and read the ETP’s prospectus carefully before investing.
